KR20220028045A - 인지 기능 향상제로서의 메틸티오니늄 - Google Patents
인지 기능 향상제로서의 메틸티오니늄 Download PDFInfo
- Publication number
- KR20220028045A KR20220028045A KR1020227003214A KR20227003214A KR20220028045A KR 20220028045 A KR20220028045 A KR 20220028045A KR 1020227003214 A KR1020227003214 A KR 1020227003214A KR 20227003214 A KR20227003214 A KR 20227003214A KR 20220028045 A KR20220028045 A KR 20220028045A
- Authority
- KR
- South Korea
- Prior art keywords
- therapeutic use
- compound
- acid
- lmtm
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/34—Coverings or external coatings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2203/00—Decoration means, markings, information elements, contents indicators
- B65D2203/02—Labels
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Mechanical Engineering (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Composite Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1909454.9 | 2019-07-01 | ||
| GBGB1909454.9A GB201909454D0 (en) | 2019-07-01 | 2019-07-01 | Enhancers |
| PCT/EP2020/068229 WO2021001306A1 (en) | 2019-07-01 | 2020-06-29 | Methylthioninium as enhancers of the cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220028045A true KR20220028045A (ko) | 2022-03-08 |
Family
ID=67539959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227003214A Ceased KR20220028045A (ko) | 2019-07-01 | 2020-06-29 | 인지 기능 향상제로서의 메틸티오니늄 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220330594A1 (https=) |
| EP (1) | EP3989977A1 (https=) |
| JP (1) | JP7686581B2 (https=) |
| KR (1) | KR20220028045A (https=) |
| CN (1) | CN114096254A (https=) |
| AU (1) | AU2020298737B2 (https=) |
| BR (1) | BR112021025330A2 (https=) |
| CA (1) | CA3143417A1 (https=) |
| GB (1) | GB201909454D0 (https=) |
| IL (1) | IL289341A (https=) |
| MX (1) | MX2021015289A (https=) |
| WO (1) | WO2021001306A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3121169T3 (da) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| DK3826639T3 (da) | 2018-07-26 | 2024-09-23 | Wista Lab Ltd | Optimeret dosering af diaminophenothiaziner i populationer |
| KR102856378B1 (ko) | 2022-09-30 | 2025-09-08 | 주식회사 젬백스앤카엘 | 4r 타우병증의 치료 또는 예방용 펩티드 |
| AU2024231880A1 (en) | 2023-03-03 | 2025-09-11 | Taurx Therapeutics Management Ltd. | Diaminophenothiazine for the treatment of microvascular brain disease disease |
| KR20240176447A (ko) | 2023-06-15 | 2024-12-24 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이의 용도 |
| KR102800994B1 (ko) | 2023-11-06 | 2025-04-29 | 주식회사 엘지에너지솔루션 | 무음극 코팅층 및 이를 포함하는 전고체 전지 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| CN101820884B (zh) * | 2007-06-19 | 2013-08-28 | 维斯塔实验室有限公司 | 用于治疗轻度认知缺损的吩噻嗪化合物 |
| CA3027974C (en) | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| EA025033B1 (ru) | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| EP2705841A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| KR102592614B1 (ko) * | 2016-07-25 | 2023-10-24 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
-
2019
- 2019-07-01 GB GBGB1909454.9A patent/GB201909454D0/en not_active Ceased
-
2020
- 2020-06-29 EP EP20735367.3A patent/EP3989977A1/en active Pending
- 2020-06-29 WO PCT/EP2020/068229 patent/WO2021001306A1/en not_active Ceased
- 2020-06-29 AU AU2020298737A patent/AU2020298737B2/en active Active
- 2020-06-29 US US17/620,956 patent/US20220330594A1/en active Pending
- 2020-06-29 JP JP2021577642A patent/JP7686581B2/ja active Active
- 2020-06-29 CA CA3143417A patent/CA3143417A1/en active Pending
- 2020-06-29 CN CN202080048926.1A patent/CN114096254A/zh active Pending
- 2020-06-29 BR BR112021025330A patent/BR112021025330A2/pt unknown
- 2020-06-29 KR KR1020227003214A patent/KR20220028045A/ko not_active Ceased
- 2020-06-29 MX MX2021015289A patent/MX2021015289A/es unknown
-
2021
- 2021-12-23 IL IL289341A patent/IL289341A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201909454D0 (en) | 2019-08-14 |
| US20220330594A1 (en) | 2022-10-20 |
| JP2022539185A (ja) | 2022-09-07 |
| WO2021001306A1 (en) | 2021-01-07 |
| CA3143417A1 (en) | 2021-01-07 |
| JP7686581B2 (ja) | 2025-06-02 |
| IL289341A (en) | 2022-02-01 |
| EP3989977A1 (en) | 2022-05-04 |
| CN114096254A (zh) | 2022-02-25 |
| MX2021015289A (es) | 2022-01-18 |
| AU2020298737B2 (en) | 2026-03-05 |
| BR112021025330A2 (pt) | 2022-02-01 |
| AU2020298737A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7686581B2 (ja) | 認知機能の向上薬としてのメチルチオニニウム | |
| EP2167095B1 (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| JP5730466B2 (ja) | 鉄の細胞内不良処理からもたらされるフリードライヒ運動失調症の治療及び/又は予防のための方法およびデフェリプロンの使用 | |
| KR102559354B1 (ko) | 치매 치료 | |
| AU2010282509B2 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| CN114080224A (zh) | 用于治疗突触病的甲基硫堇鎓 | |
| US9161936B2 (en) | Laquinimod for treatment of GABA mediated disorders | |
| US20230031369A1 (en) | Therapeutic interactions of leucomethylthioninium | |
| TW201618760A (zh) | 使用半胱胺組合物治療亨廷頓氏病之方法 | |
| RU2824584C2 (ru) | Метилтиониний в качестве усилителя когнитивной функции | |
| RU2834773C2 (ru) | Терапевтические взаимодействия лейкометилтиониния | |
| US20210085692A1 (en) | Agents, compositions and methods for treating and preventing alzheimer's disease | |
| KR20160085757A (ko) | 다발성 경화증의 치료를 위한 라퀴니모드 병용 치료 | |
| HK1136965B (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| HK1136965A (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| WORKS | Current |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |